TCGA-BB-4228-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.560
- G2M_CHECKPOINT+0.380
- MYC_TARGETS_V1+0.290
- SPERMATOGENESIS+0.230
- DNA_REPAIR+0.190
- MYC_TARGETS_V2+0.140
- BILE_ACID_METABOLISM+0.090
- OXIDATIVE_PHOSPHORYLATION+0.090
- MITOTIC_SPINDLE+0.070
- FATTY_ACID_METABOLISM+0.040
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- INTERFERON_GAMMA_RESPONSE-0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
- APICAL_JUNCTION-0.300
- INFLAMMATORY_RESPONSE-0.290
- CHOLESTEROL_HOMEOSTASIS-0.280
- MYOGENESIS-0.280
- COMPLEMENT-0.270
- PROTEIN_SECRETION-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_Z45HD492 | medulloblastoma | — | 0.855 |
| 2 | SRR5088911 | — | — | 0.833 |
| 3 | BS_SKGJ5SY9 | medulloblastoma | — | 0.829 |
| 4 | C3L-00965 | — | cohortSQ2 | 0.829 |
| 5 | BS_09Z7TC35 | medulloblastoma | — | 0.825 |
| 6 | BS_E3BAT4C1 | medulloblastoma | — | 0.823 |
| 7 | SRR8518301 | — | E | 0.819 |
| 8 | BS_EFE4YEK3 | medulloblastoma | — | 0.818 |
| 9 | C3L-04013 | — | cohortMD1 | 0.813 |
| 10 | BS_M86ECPHK | Embryonal tumors | — | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |